- Lobbying
- Lobbying by Merck & Co., Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Dave Boyer | Sp Ast Pres LA; Ast Com Leg, FDA; Sp Ast Sec HHS; Con Asst, Off of WH Liaison DoD; Con Asst, Off of Sec Lab See prior filing |
Ryan Long | LC Rep Norwood; LA & LD Rep Barton;Prof. Staff, Csel, & Chief Csel Hse E&C Ctme See prior filing |
Brent Del Monte | See prior filing LA/LD Rep. Tom Bliley; Counsel House Energy & Commerce Committee |
Robb Walton | Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Healthcare Aide Sen. Enzi See prior filing |
John Stone | Counsel, House E&C Cmte, Oversight Subcmte; Senior Counsel,House E&C Cmte Health Subcmte See prior filing |
Matthew Hoffmann | St. Asst. Rep. Vitter; LC Rep. Vitter; Sen. LC .Rep. Vitter; LA Rep. Paul Ryan; Sen. LA Rep. Paul Ryan; LD Rep. Paul Ryan; Budget Analyst Rep. Paul Ryan; St. Dir. Health Subcmte House W&M Cmte; Policy Analyst Off. Speaker; Policy Dir. Sen. Fin Cmte. See prior filing |
Remy Brim | Senior FDA Policy Advisor to the Senate HELP Committee Ranking Member, Sen. Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren See prior filing |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally, and/ Merck specifically..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate